Please assess the completion status of the following clinical trial:

Trial Title: A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is a male or female subject 40 years of age or older~* Subject must have a negative pregnancy test, and must be prepared to use effective contraception if of child-bearing potential~* Subject is capable of performing reproducible spirometry maneuvers~* Subject has post-bronchodilator FEV1/FVC ratio \<0.7~* Subject has moderate-to-severe stable COPD (Stage 2 or 3 according to the GOLD Guidelines)~* Subject has a post-bronchodilator FEV1 greater than or equal to 30% and less than 80% of predicted normal~* Subject has a current or past smoking history of at least 10 pack-years.~Exclusion Criteria:~* Subject has a significant respiratory disease or disorder other than COPD that would affect the interpretation of data from this study~* Subject has a history of reactions or hypersensitivity to inhaled or nebulized anticholinergic or beta-agonist agents~* Subject suffers from any medical condition that would preclude the use of inhaled anticholinergic agents~* Subject has been hospitalized for COPD or pneumonia within 12 weeks~* Subject requires long-term oxygen therapy (\>15 hours a day)

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- 44 mcg (Type: EXPERIMENTAL): TD-4208
- 88 mcg (Type: EXPERIMENTAL): TD-4208
- 175 mcg (Type: EXPERIMENTAL): TD-4208
- 350 mcg (Type: EXPERIMENTAL): TD-4208

Based on this trial design, predict the completion outcome and termination type (if applicable).